Highlights: Positive results from phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD); rapid and sustained response for patients receiving a single 25mg dose of COMP360 psilocybin with psychological support Positive results from open-label study of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in TRD Launch of phase II study of COMP360…


Previous articlePT296 – Dr. David Luke – Vital Psychedelic Conversations
Next articlePsychedelic Bulletin: Following the Money – How Much do Psychedelics Companies Spend on R&D?